Selecting the right patient for tumor therapy

Research output: Contribution to journalShort surveypeer-review

23 Scopus citations


Two clinical studies have identified mutations affecting the EGF receptor in lung cancers from patients who respond robustly to gefitinib, a small-molecule inhibitor of the receptor tyrosine kinase. This work highlights the importance of conducting clinical trials with an eye to delivering molecule-targeted therapeutics to those patients most likely to benefit.

Original languageEnglish (US)
Pages (from-to)577-578
Number of pages2
JournalNature medicine
Issue number6
StatePublished - Jun 2004

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology


Dive into the research topics of 'Selecting the right patient for tumor therapy'. Together they form a unique fingerprint.

Cite this